Sodium-glucose cotransporter-2 inhibitors beyond glycemic control: Their role in acute kidney injury recovery

Table 1 Summary of evidence and research quality evaluation for studies on sodium-glucose cotransport protein 2 inhibitors in acute kidney injury

No.	Trial name	Phase	Drug	Inclusion population	Primary endpoints	Expected completion date
1	Recover-AKI	II	Empagliflozin	Patients with AKI	AKI recovery and MAKE365	Late 2025
2	Defender	III	Dapagliflozin 10 mg	Patients with acute organ dysfunction in ICU	Hospital mortality, use of kidney replacement therapy, ICU stay	Completed 2023
3	Discover pilot	III	Dapagliflozin 10 mg	Patients post AKI recovery	Renal functions after 12 weeks	Expected approximately 2025
4	Prevents-AKI	III	Dapagliflozin 10 mg	Patient in ICU at risk of AKI	Incidence of new and worsening AKI	Expected approximately 2027
5	CI AKI prevention (NCT04853615)	II	Empagliflozin 25 mg	Diabetic CKD patients undergoing contrast procedures	Incidence of contrast induced AKI in diabetic kidney	Approximately 2025-2026 (unknown status)
6	DAPA-PCI-AKI	IV	Dapagliflozin 10 mg	Patients undergoing coronary angioplasty at risk of AKI	Incidence of AKI post percutaneous coronary intervention	Expected 2025
7	JAMA network open study	Cohort study	SGLT2 inhibitors	Patients with type 2 diabetes and AKD	Mortality and MAKE in T2D patients with AKD	Completed 2024

AKI: Acute kidney injury; MAKE365: Major adverse kidney events; SGLT2: Sodium-glucose cotransport protein 2; CKD: Chronic kidney disease; ICU: Intensive care unit; CPI: Percutaneous coronary intervention; JAMA: Journal of the American Medical Association; DAPA: Dapagliflozin; CI: Confidence interval.